GLP Watchdog
FDA-Approved MedicationUpdated August 14, 2026

Zepbound Guide

Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesZepbound
FDA StatusFDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)[1]
Approval DateNovember 8, 2023[1]

How Zepbound Works

Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]

Dosing Schedule

Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (maintenance)

Side Effects

Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), suicidal ideation monitoring recommended, thyroid tumor risk noted in animal models.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 22.5% (about 52 lbs) over 72 weeks — the highest of any anti-obesity medication ever studied. At 10mg, participants lost 21.4%; at 5mg, they lost 15.0%. 91% of participants lost at least 5% of body weight at the 15mg dose.[2][3]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Zepbound

These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.

8.8/ 10

AskRx

Best for: coverage in all 50 states, which most of the register will not confirm

★★★★☆4.4/5

Editorial score · methodology

$199/mo
BrandSemaglutideTirzepatide
Get StartedRead full AskRx review →
8.4/ 10

Vaylen

Best for: bloodwork inside the $179/month rather than billed on top

★★★★☆4.2/5

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Vaylen review →
8.4/ 10

BiltRx

Best for: moving between compounded and brand without changing seller

★★★★☆4.2/5

Editorial score · methodology

$125/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full BiltRx review →
8.3/ 10

HeliMeds

Best for: moving between compounded and brand without changing seller

★★★★☆4.2/5

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full HeliMeds review →
8.2/ 10

Effecty

Best for: moving between compounded and brand without changing seller

★★★★☆4.1/5

Editorial score · methodology

$60/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.9/ 10

Rex MD

Best for: coverage in all 50 states, which most of the register will not confirm

★★★★☆4/5

Editorial score · methodology

$199/mo
BrandSemaglutideTirzepatideSermorelin
Get StartedRead full Rex MD review →

Cost Comparison

Zepbound cost & pricing →Savings & coupons →Side effects →Dosing & titration →How to get it →Storage & handling →Alternatives →Manufacturer coupon →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
Evernow$49/moVisit
The Virtual NP$75/moVisit
FORM$95/moVisit
MEDVi$99/moVisit
Wisp$99/moVisit
Kin Meds$149/moVisit
AskRx$299/moVisit
GoodRx$299/moVisit
Klinic$299/moVisit
PreventiveMD$299/moVisit
Knownwell$349/moVisit
Rex MD$349/moVisit
Aspire Health$374/moVisit
RxSpan MD$1069/moVisit
Vaylen$1086/moVisit
altRX$1249/moVisit
Effecty$1300/moVisit
HeliMeds$1396/moVisit
Aquivia Health$1399/moVisit
Luvo Health$1399/moVisit
BiltRx$1499/moVisit
NuuVim$1892/moVisit

Zepbound Head-to-Head Comparisons

Short-form verdict pages comparing Zepbound to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Zepbound vs Wegovy
A real head-to-head exists here, which is rare. SURMOUNT-5 put Zepbound at 20.2% against Wegovy at 13.7% over 72 weeks, matching what their separate trials had suggested.
Last verified 2026-05-27
Zepbound vs Mounjaro
One molecule from one manufacturer under two names. The label is the whole difference: diabetes on one side, obesity and sleep apnea on the other, at identical doses and identical cash prices.
Last verified 2026-05-27
Zepbound vs Ozempic
Different molecules, different labels, and a head-to-head that favors one clearly: 20.2% against 13.7% at 72 weeks in SURMOUNT-5.
Last verified 2026-05-27
Zepbound vs Foundayo
Both are approved for weight, which makes this a rare like-for-like comparison. The injection takes off about twice as much; the pill needs no needle and no food rules.
Last verified 2026-05-27
Zepbound vs Saxenda
Saxenda is a daily injection approved from age 12. Zepbound is a weekly injection, adults only, at roughly three times the weight loss and a third of the cash price.
Last verified 2026-05-28
Zepbound vs Rybelsus
Rybelsus is daily oral semaglutide, labeled for diabetes only, with a strict 30-minute fast. Zepbound is weekly tirzepatide, labeled for weight and sleep apnea. About 4% against about 21%.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Pivotal Zepbound Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Zepbound label, with primary-source numbers and FAQs.

SURMOUNT-1
SURMOUNT-1 put tirzepatide at 5, 10 and 15 mg weekly against placebo in 2,539 adults who had obesity, or excess weight plus a related complication. The top dose reached -20.9% body weight at 72 weeks against -3.1% on placebo — more than any approved weight drug had achieved in a phase 3 trial, and the evidence behind Zepbound's approval. It also reset what the whole market claims it can deliver, including products carrying no trial evidence whatsoever.
3 · N=2,539 · Last verified 2026-05-27
SURMOUNT-OSA
SURMOUNT-OSA tested tirzepatide in 469 people carrying obesity alongside moderate-to-severe obstructive sleep apnea, split into two cohorts — those using positive airway pressure and those not. The apnea-hypopnea index fell 25.3 events an hour without PAP and 29.3 with it, against roughly 5 on placebo. It produced a second FDA indication for Zepbound and turned a weight-management drug into a treatment for a specific, diagnosable condition.
Phase 3 · N=469 · Last verified 2026-05-28
SURMOUNT-2
SURMOUNT-2 ran tirzepatide in the population SURMOUNT-1 excluded: adults with type 2 diabetes as well as obesity. At 15 mg the result was −14.7% body weight at 72 weeks against −3.2% on placebo. That is a substantial effect and it is six percentage points below what the same drug produced in people without diabetes, which is the single most useful comparison anyone with diabetes can make when reading marketing built on SURMOUNT-1.
3 · N=938 · Last verified 2026-05-28
SURMOUNT-3
SURMOUNT-3 answered a question the other trials skip: what does the drug add for someone who has already succeeded with lifestyle change? All 579 participants completed a 12-week intensive lifestyle lead-in first. Those randomized to tirzepatide then lost a further 18.4%; those on placebo regained 2.5%. The design isolates the drug's contribution on top of behavioral success rather than instead of it.
3 · N=579 · Last verified 2026-05-28

Zepbound Patient Questions, Answered

Real patient questions about Zepbound pulled from named subreddits and answered with peer-reviewed trial data.

The 10 Tirzepatide Questions People Actually Ask, Answered From the Trials
10 questions · 11 PubMed citations
Last verified 2026-05-27
GLP-1 Coverage: the 10 Questions People Ask After a Denial
10 questions · 12 PubMed citations
Last verified 2026-05-28

Zepbound Reference Cards

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Zepbound Dose Steps 2026: Ladder, Ceiling and the 96-Hour Rule
The Zepbound ladder is often described as six steps to 15 mg, which quietly implies 15 mg is where you are meant to end up. The label says something different: raise the dose in 2.5 mg increments until you reach a maintenance dose that works, and three doses qualify — 5, 10 and 15 mg. This page sets out the steps, the four-day window for a missed dose, the 72-hour rule for moving injection day, and the symptoms that mean stop climbing.
4 min read · Last verified 2026-05-27
GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid
Every weekly GLP-1 permits the same three injection sites and every one of them tells you to move around. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.
4 min read · Last verified 2026-05-28
Switching Between GLP-1s: Why You Start at the Bottom Again
Switching is common — a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose — and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Zepbound

Curated lists of the highest-impact peer-reviewed studies on Zepbound and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

The 10 Tirzepatide Trials That Built the Case (2026)
Tirzepatide is the only dual GIP and GLP-1 agonist with a finished phase 3 obesity program, and the ten trials below are why it currently sits at the top of the evidence. They cover the pivotal result, what happens in diabetes, what happens when you stop, the direct comparison against semaglutide, and two indications — sleep apnea and heart failure — that have nothing to do with the scale.
10 ranked papers · Last verified 2026-08-16
GLP-1s and Bone: 10 Studies on a Risk Nobody Has Measured Properly
Losing weight quickly costs bone density no matter how it is done. Whether these drugs add anything on top of that is unsettled — one randomized trial says they protect bone, another says the drug alone loses more density than exercise alone. The fracture meta-analyses are reassuring and underpowered, and no trial has followed a non-diabetic obesity population long enough to matter.
10 ranked papers · Last verified 2026-08-16
Are GLP-1s Worth What They Cost? 10 Economic Analyses (2026)
Nobody in this literature disputes that the drugs work. What they disagree about is whether the price is defensible, and the answer flips depending on four things: which population, list price or net price, which country, and who paid for the model. This list covers the analyses that coverage decisions are actually argued from.
10 ranked papers · Last verified 2026-08-16

Related Research on Zepbound

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Medicare and GLP-1s: the $50 Bridge That Opened in July
Since 1 July 2026 Medicare provides access to certain GLP-1 drugs for weight management at a $50 monthly copay, through a temporary program running outside Part D. Eligibility, covered drugs, and the Zepbound restriction most people miss.
6 min read3 citations
Is Zepbound a Semaglutide? Brand Names vs Molecules
No — Zepbound is tirzepatide, the same molecule as Mounjaro. Nine brand names cover five molecules, and knowing which is which decides your price and your coverage.
6 min read3 citations
Where to Inject a GLP-1, and Why Rotation Matters
Abdomen, front of thigh, or back of the upper arm — subcutaneous, never muscle. The instruction people skip is rotation, and skipping it can look exactly like the drug failing.
6 min read3 citations
The Cheapest Way to Get a GLP-1 Without Insurance
Compounded semaglutide runs $79 to $299 a month across 556 sellers; tirzepatide $99 to $399. The spread is four to one for the same molecule — here is what decides where you land.
8 min read3 citations
How to Get a GLP-1 Covered by Insurance
Coverage is decided in three steps, and most people give up at the wrong one. An exclusion and a denial are different things — only one of them is worth appealing.
8 min read3 citations
Do GLP-1 Patches Work? The Molecule Is Too Big
Skin stops molecules above roughly 500 daltons. Semaglutide weighs 4,114 and tirzepatide 4,813. No adhesive patch changes that, and no GLP-1 patch is FDA-approved.
7 min read4 citations

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.